- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis (CPP)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 468.1KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 112.3KB)
Bimekizumab – November 2025
Bimekizumab: Injection 320 mg in 2 mL single use pre-filled pen; Bimzelx® - November 2025
Last updated
5 November 2025